Group One Trading’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-61,730
| Closed | -$8.03K | – | 8001 |
|
|
2025
Q3 | $8.03K | Buy |
+61,730
| New | +$8.47K | ﹤0.01% | 7305 |
|
|
2025
Q2 | – | Sell |
-147
| Closed | -$39 | – | 7859 |
|
|
2025
Q1 | $29 | Sell |
147
-20,368
| -99% | -$10.5K | ﹤0.01% | 7434 |
|
|
2024
Q4 | $11.1K | Sell |
20,515
-27,855
| -58% | -$20.3K | ﹤0.01% | 6054 |
|
|
2024
Q3 | $46K | Buy |
48,370
+14,333
| +42% | +$16.3K | ﹤0.01% | 4713 |
|
|
2024
Q2 | $33.2K | Buy |
34,037
+11,670
| +52% | +$12.8K | ﹤0.01% | 4834 |
|
|
2024
Q1 | $35.3K | Buy |
22,367
+22,316
| +43,757% | +$26.9K | ﹤0.01% | 4997 |
|
|
2023
Q4 | $40 | Buy |
+51
| New | +$29 | ﹤0.01% | 7237 |
|
|
2023
Q3 | – | Sell |
-16,541
| Closed | -$13.9K | – | 7562 |
|
|
2023
Q2 | $15.3K | Hold |
16,541
| – | – | ﹤0.01% | 6156 |
|
|
2023
Q1 | $18K | Sell |
16,541
-2,491
| -13% | -$3.86K | ﹤0.01% | 5580 |
|
|
2022
Q4 | $27.8K | Sell |
19,032
-2,000
| -10% | -$3.24K | ﹤0.01% | 5398 |
|
|
2022
Q3 | $23K | Buy |
21,032
+2,000
| +11% | +$3.67K | ﹤0.01% | 5958 |
|
|
2022
Q2 | $32K | Sell |
19,032
-3,200
| -14% | -$5.5K | ﹤0.01% | 5928 |
|
|
2022
Q1 | $46K | Buy |
22,232
+326
| +1% | +$880 | ﹤0.01% | 6152 |
|
|
2021
Q4 | $82K | Buy |
21,906
+15,132
| +223% | +$68.9K | ﹤0.01% | 5899 |
|
|
2021
Q3 | $35K | Sell |
6,774
-44,955
| -87% | -$202K | ﹤0.01% | 6804 |
|
|
2021
Q2 | $220K | Buy |
51,729
+35,672
| +222% | +$173K | ﹤0.01% | 5149 |
|
|
2021
Q1 | $85K | Buy |
16,057
+15,563
| +3,150% | +$89.1K | ﹤0.01% | 5801 |
|
|
2020
Q4 | $3K | Sell |
494
-121
| -20% | -$657 | ﹤0.01% | 6141 |
|
|
2020
Q3 | $5K | Sell |
615
-28,006
| -98% | -$245K | ﹤0.01% | 5619 |
|
|
2020
Q2 | $287K | Buy |
+28,621
| New | +$180K | ﹤0.01% | 3082 |
|
|
2019
Q2 | – | Sell |
-6,643
| Closed | -$27.1K | – | 4885 |
|
|
2019
Q1 | $29K | Sell |
6,643
-12,882
| -66% | -$60K | ﹤0.01% | 3851 |
|
|
2018
Q4 | $112K | Buy |
19,525
+9,547
| +96% | +$70.4K | ﹤0.01% | 3102 |
|
|
2018
Q3 | $135K | Buy |
9,978
+7,219
| +262% | +$75.7K | ﹤0.01% | 3310 |
|
|
2018
Q2 | $33K | Buy |
+2,759
| New | +$34.4K | ﹤0.01% | 4158 |
|
|
2018
Q1 | – | Sell |
-200
| Closed | -$1.75K | – | 4762 |
|
|
2017
Q4 | $1K | Hold |
200
| – | – | ﹤0.01% | 4735 |
|
|
2017
Q3 | $2K | Buy |
+200
| New | +$1.25K | ﹤0.01% | 4624 |
|
|
2016
Q4 | – | Sell |
-2,500
| Closed | -$18K | – | 4378 |
|
|
2016
Q3 | $18K | Buy |
+2,500
| New | +$19.1K | ﹤0.01% | 3822 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Group One Trading's ADAP Position: Q4 2025 in Review
Group One Trading sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 61,730 shares — an estimated $8.03K sold.
Group One Trading first reported a position in ADAP in Q3 2016 and held it in 27 quarters. The position peaked at $287K in Q2 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- Group One Trading reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 61,730 Adaptimmune Therapeutics shares in Q4 2025, an estimated $8.03K.
- Group One Trading first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 27 quarters.
- Group One Trading's Adaptimmune Therapeutics position peaked at $287K in Q2 2020.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.